Latest news for GSK (OTC:GLAXF) Stock

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AACS

AAON

AAUKF

ACDSF

ACGL

ACIA

ACLS

ADBE

ADSK

ADYYF

AFFY

AFGC

AIQUY

AJMPF

AKAM

ALCO

ALFVY

ALLE

ALLT

AMADY

AMAT

AMBC

AMED

AMIGF

AMRC

AMWD

ANCUF

ANSLY

ANSS

AOMFF

AOMOY

APAM

APPF

ARBV

ARES

ASAZF

ASAZY

ASHTY

ASPN

ASYS

ATCMF

ATLC

ATRC

ATVI

ATZAF

AUDC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BAESY

BANF

BASI

BATRA

BCPC

BCUCY

BEVFF

BF-A

BF-B

BHOOY

BIOS

BKRKY

BLDP

BLSP

BMDPY

BORT

BPOP

BRK-A

BRK-B

Stocks That Hit 52-Week Highs On Friday

AAPL

ACRE

AGRO

ALGT

APTO

APTV

ARDX

ASMIY

AWWI

AXAHF

AXAHY

AZNCF

BABA

BHLB

BMTC

BNDSY

BRBR

BXMT

CACI

CBRE

CBSH

CDAY

CHGS

CHRYY

CIVB

CMRE

COHU

CROX

CRTX

DIOD

EFSC

ELTZ

ENLAY

ENTG

EPAY

ESKYF

ESSYY

Eaton Vance Tax-Managed Diversified Equity

Eaton Vance Tax-Managed Global Diversified Equit

AACAY

AAVXF

ABCZY

AHEXY

AHFD

AINV

AMGN

AMIGY

AMKBF

AMRN

AMTB

ANSLF

ARGKF

ARGX

ARNC

AROW

ASBFY

ASGN

ASML

ASNB

ATDRY

ATLKY

AXSM

AZMTF

BBSEY

BCKIF

BCLYF

BNPQY

BNTX

BRKL

BTDPY

BTLCY

BTSGY

BURBY

CARO

CDUAF

CHDN

CIFAF

CLSD

CNOB

CODGF

CODI

CODYY

CRAI

CRD-A

CREIY

CRHCF

Stocks That Hit 52-Week Highs On Tuesday

GSK PLC

International Wide-Moat Stocks On Sale - The May 2024 Heat Map

GSK Breathes New Life Into Asthma Treatment With Depemokimab

CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements

Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows

GSK plc: Long-Term Cash Cow

ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting

Amgen: You Haven't Seen Anything Yet

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That&rsquo;s because most retail investors prefer to research consumer information regarding stock picks through the calculations of those deemed more experienced in understanding financial fundamentals. No industry is this speculation more important than in biotech. This is where most companies are valued based on the future potential of their products rather than their present earnings. As a result, some undervalued <a href="https://investorplace.com/industries/technology/" target="_blank">tech stocks</a> slip through the mainstream cracks.</p>



<p>Yet, these novel and exciting companies can often have generous upsides depending on the therapeutic outcomes of their early clinical trials and the total addressable market of patients they aim to treat. As such, investors looking to take advantage of presently undervalued <a href="https://investorplace.com/industries/healthcare/biotech/" target="_blank">biotech stocks</a> should keep a close eye on drug pipelines and the mechanism by which the drugs operate for insight into the future reception of the product.</p>



<p>Here are the three undervalued <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>:</p>



<h2>Undervalued Biotech Stocks: Vir Biotechnology (VIR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Specializing in biotechnology for viral prophylactics and treatments, <strong>Vir Biotechnology </strong>(NASDAQ:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/vir-stock-quote/">VIR</a></strong>) has started getting attention from a few analysts. This company&rsquo;s approach to therapeutics focuses on a <a target="_blank" href="https://www.vir.bio/pipeline/">broad pipeline</a> across several disease types. It achieves this while collaborating with major biotech firms like <strong>Gilead </strong>(NASDAQ:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a></strong>) and <strong>GSK </strong>(OTCMKTS:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/glaxf-stock-quote/">GLAXF</a></strong>). As a result, the company has been able to rapidly test medicines for diseases like Hepatitis B, HIV, and HPV.</p>



<p>Considering these diseases&rsquo; burden on healthcare systems worldwide, VIR has several avenues for developing profit. As a result, some analysts put it at a high price <a target="_blank" href="https://www.marketwatch.com/investing/stock/vir/analystestimates">target of $110</a>. That&rsquo;s a stunning 1,000% upside from its current price of around $9.18.</p>



<p>Thus, investors who are bullish on viral biotechnology should consider VIR. It has a wide range of collaborative partners to lean on and several potentially market-changing therapeutics in the works.</p>



<h2>IO Biotech (IOBT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cancer-300x169.jpg" alt="A variety of pills, pill bottles, and droppers arranged on a table in multiple bright colors."><div>Source: Shutterstock</div></div><p>While a cancer vaccine might sound like something straight out of a movie, <strong>IO Biotech </strong>(NASDAQ:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/iobt-stock-quote/">IOBT</a></strong>) has been working to make it a reality. As a disclaimer, the company trades around the one-dollar mark and has a market capitalization below $100 million, so it is like a penny stock.</p>



<p>The company has an intriguing pipeline of cancer prophylactics in the works. Specifically, its focus has been on melanoma, lung, and head and neck cancers. This is significant because lung cancer has one of the <a target="_blank" href="https://www.researchgate.net/figure/Most-common-cancer-cases-in-2018-all-around-the-world_fig1_343808729">highest incidence rates</a> at around 11%, with a mortality rate of over 18%, according to some metrics.</p>



<p>As such, should IOBT succeed in establishing its immune-modulating cancer vaccine as the backbone of combination therapy for people with cancer, its stock value could rise rapidly to meet <a target="_blank" href="https://www.tipranks.com/stocks/iobt/forecast#:~:text=The%20average%20price%20target%20for,the%20current%20price%20of%20%241.17.">analyst forecasts</a> of $12 from its current $1.18 price.</p>



<h2>Axsome Therapeutics (AXSM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/axsm-stock-300x169.jpg" alt="A magnifying glass zooms in on the Axsome Therapeutics, Inc. (AXSM) logo"><div>Source: Pavel Kapysh/Shutterstock.com</div></div><p>Let&rsquo;s look at a well-established pharmaceutical company with a track record of successful central nervous system treatments. <strong>Axsome Therapeutics </strong>(NASDAQ:<strong><a href="https://investorplace.com/stock-quotes/axsm-stock-quote/" target="_blank">AXSM</a></strong>) has bullish analysts despite downtrodden financial metrics. Estimates put the stock at <a href="https://www.marketwatch.com/investing/stock/axsm/analystestimates" target="_blank">$190 a share</a> as an ideal price target, up from its current $81 price tag. Yet, these predictions don&rsquo;t come from the fact that the company&rsquo;s net losses reached <a href="https://www.google.com/finance/quote/AXSM:NASDAQ?sa=X&amp;ved=2ahUKEwjMq7ei2YqHAxUBgf0HHdkoApwQ3ecFegQIPxAf" target="_blank">$68.36 million</a>. This was alongside a net profit margin of -91% for Q1 2024.</p>



<p>Instead, analysts are bullish on AXSM&rsquo;s <a target="_blank" href="https://www.axsome.com/axs-portfolio/pipeline">drug pipeline</a>. The company recently saw its AXS-05 Alzheimer&rsquo;s drug receive breakthrough therapy designation from the Food and Drug Administration. This, paired with its narcolepsy drug, AXS-12, receiving orphan drug designation, has put its potential for new revenue streams exceptionally high.</p>



<p>As such, AXSM represents a classic play in the undervalued biotech stocks investing world. It&rsquo;s the game of predicting if a new drug coming to market will spike the stock&rsquo;s price.</p>



<p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Viktor Zarev&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-undervalued-biotech-gems-with-200-analyst-price-targets/">3 Undervalued Biotech Gems With 200%+ Analyst Price Targets</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

GSK

News

Latest news for GSK (OTC:GLAXF) Stock

Tuesday, March 24, 2020

Friday, January 17, 2020

Friday, December 20, 2019

Monday, December 16, 2019

Friday, December 13, 2019

Monday, September 30, 2019